Nadler Financial Group Inc. Decreases Stock Holdings in Abbott Laboratories $ABT

Nadler Financial Group Inc. reduced its position in Abbott Laboratories (NYSE:ABT) by 11.8% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,828 shares of the healthcare product maker’s stock after selling 1,183 shares during the quarter. Nadler Financial Group Inc.’s holdings in Abbott Laboratories were worth $1,201,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also bought and sold shares of the company. Hughes Financial Services LLC purchased a new stake in Abbott Laboratories in the first quarter worth $27,000. Abound Financial LLC purchased a new stake in Abbott Laboratories in the first quarter worth $28,000. Elequin Capital LP purchased a new stake in Abbott Laboratories in the first quarter worth $30,000. JCIC Asset Management Inc. purchased a new stake in Abbott Laboratories in the first quarter worth $32,000. Finally, Vision Financial Markets LLC purchased a new position in shares of Abbott Laboratories in the first quarter valued at $33,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Price Performance

NYSE:ABT opened at $131.52 on Tuesday. The firm has a market capitalization of $228.90 billion, a price-to-earnings ratio of 16.48, a P/E/G ratio of 2.51 and a beta of 0.69. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23. The stock has a fifty day moving average of $132.57 and a 200 day moving average of $131.60. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.26. The company had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The firm’s quarterly revenue was up 7.4% on a year-over-year basis. During the same quarter last year, the company earned $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, research analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be paid a dividend of $0.59 per share. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $2.36 annualized dividend and a yield of 1.8%. Abbott Laboratories’s payout ratio is 29.57%.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the sale, the chief financial officer owned 51,003 shares of the company’s stock, valued at $6,862,453.65. The trade was a 9.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.46% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Raymond James Financial reduced their price target on Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating for the company in a research report on Friday, July 18th. Mizuho lifted their price target on Abbott Laboratories from $130.00 to $140.00 and gave the company a “neutral” rating in a research report on Wednesday, July 16th. Evercore ISI lifted their price target on Abbott Laboratories from $140.00 to $144.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th. Leerink Partnrs upgraded Abbott Laboratories to a “hold” rating in a research report on Monday, June 16th. Finally, Leerink Partners assumed coverage on Abbott Laboratories in a research report on Monday, June 16th. They issued a “market perform” rating and a $143.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $146.17.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.